Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an update.
Shanghai Junshi Biosciences Co., Ltd. announced that the U.S. FDA has approved its investigational new drug application for a phase II/III clinical study of JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, for the neoadjuvant treatment of non-small cell lung cancer (NSCLC) patients. This approval marks a significant step for the company as it positions JS207 as a potential new treatment option for NSCLC, addressing unmet clinical needs and potentially improving patient outcomes in a highly prevalent and deadly cancer type.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a pharmaceutical company based in China, specializing in the development of innovative drugs for the treatment of advanced malignant tumors. The company focuses on creating bispecific antibodies, such as JS207, which target both PD-1 and VEGF pathways to enhance anti-tumor activity.
Average Trading Volume: 12,050,397
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.92B
For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.